Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study.
Nikolay A Shamalov, Mikhail Yu Martynov, Elena B Yarovaya...
https://pubmed.ncbi.nlm.nih.gov/41293810/Actively Recruiting
Led by Supergene, LLC · Updated on 2026-10-01
990
Participants Needed
17
Research Sites
8 weeks
Total Duration
Researchers are evaluating the recombinant non-immunogenic staphylokinase in patients who have suffered an acute ischemic stroke within 4.5 to 24 hours after symptom onset. This phase III, multicenter, double-blind, randomized, placebo-controlled trial focuses on patients with large vessel occlusion in the anterior circulation and salvageable brain tissue. The study aims to determine if this treatment is effective and safe when given beyond the currently recommended 4.5-hour window for intravenous thrombolysis. Participants will be randomly assigned to receive either a single intravenous bolus of 10 mg non-immunogenic staphylokinase or a placebo injection immediately after randomization. The bolus is administered rapidly within 5 to 10 seconds and is not adjusted by body weight. Patients intended for direct thrombectomy are excluded. The study includes a follow-up period of 90 days to assess outcomes. During the trial, participants will undergo neuroimaging assessments such as CT or MRI to confirm eligibility and monitor brain perfusion. Researchers will measure functional outcomes using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days. They will also monitor reperfusion rates, mortality, and any adverse events. This comprehensive evaluation will help assess the treatments impact on restoring blood flow and improving recovery after stroke.
CONDITIONS
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
N
Nikolay A. Shamalov, MD, prof
N
Natalya A. Marskaya
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Supergene, LLC
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment at enrollment
Participants receive either a single intravenous bolus of non-immunogenic staphylokinase or a placebo within 5 to 10 seconds immediately after randomization.
1 visit (in-person)
Duration - 90 days
Participants are monitored over 90 days to assess functional recovery, reperfusion, and any adverse events through clinical evaluations and imaging.
Multiple visits over 90 days
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Nikolay A Shamalov, Mikhail Yu Martynov, Elena B Yarovaya...
https://pubmed.ncbi.nlm.nih.gov/41293810/Eugene I Gusev, Mikhail Yu Martynov, Alexey A Nikonov...
https://pubmed.ncbi.nlm.nih.gov/34418399/Supergene, LLC
Lead Sponsor